Phase I trial of a novel anti-GD2 monoclonal antibody, hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma

Journal of Clinical Oncology

Volumn 32, Issue 14, 2014, Pages 1445-1452

  Navid, Fariba ^a,b   Sondel, Paul M ^d   Barfield, Raymond ^e   Shulkin, Barry L ^a   Kaufman, Robert A ^a,b   Allay, Jim A ^c   Gan, Jacek ^d   Hutson, Paul ^d   Seo, Songwon ^d   Kim, KyungMann ^d   Goldberg, Jacob ^d   Hank, Jacquelyn A ^d   Billups, Catherine A ^a   Wu, Jianrong ^a   Furman, Wayne L ^a,b   McGregor, Lisa M ^a,b   Otto, Mario ^d   Gillies, Stephen D ^f   Handgretinger, Rupert ^g   Santana, Victor M ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c Children's GMP   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f Provenance Biopharmaceuticals   (United States)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ALANINE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; DIPHENHYDRAMINE; HEMOGLOBIN; HU14.18K322A; HYDROXYZINE; LYSINE; MONOCLONAL ANTIBODY; MORPHINE SULFATE; PARACETAMOL; UNCLASSIFIED DRUG; CH14.18 MONOCLONAL ANTIBODY;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER IMMUNOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EYE DISEASE; FEBRILE CONVULSION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; HYPOALBUMINEMIA; HYPONATREMIA; HYPOTENSION; IMMUNOGENICITY; LETHARGY; LYMPHOCYTOPENIA; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROBLASTOMA; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; POINT MUTATION; PRIORITY JOURNAL; PRURITUS; SENSORY NEUROPATHY; SERUM SICKNESS; SINUS TACHYCARDIA; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR RECURRENCE; BRAIN TUMOR; PRESCHOOL CHILD; RECURRENT DISEASE;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; NEUROBLASTOMA; RECURRENCE;

EID: 84902962349     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.4423     Document Type: Article

References (51)

1. Simon T, Hero B, Faldum A, et al: Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer 11:21, 2011
2. Yu AL, Gilman AL, Ozkaynak MF, et al: Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:1324-1334, 2010
3. Navid F, Santana VM, Barfield RC: Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets 10:200-209, 2010
4. Simon T, Hero B, Faldum A, et al: Consolidation treatment with chimeric anti-GD2 antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 22:3549-3557, 2004 (Pubitemid 41103661)
5. Isaacs JD, Greenwood J, Waldmann H: Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function. J Immunol 161:3862-3869, 1998 (Pubitemid 28468959)
6. Sorkin LS, Otto M, Baldwin WM 3rd, et al: Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain 149:135-142, 2010
7. Niwa R, Shoji-Hosaka E, Sakurada M, et al: Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 64:2127-2133, 2004
8. Shinkawa T, Nakamura K, Yamane N, et al: The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278:3466-3473, 2003 (Pubitemid 36801263)
9. Ahn C: An evaluation of phase I cancer clinical trial designs. Stat Med 17:1537-1549, 1998
10. Storer BE: Design and analysis of phase I clinical trials. Biometrics 45:925-937, 1989
11. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
12. Ady N, Zucker JM, Asselain B, et al: A new 123I-MIBG whole body scan scoring method: Application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 31A:256-261, 1995
13. Messina JA, Cheng SC, Franc BL, et al: Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 47:865-874, 2006 (Pubitemid 44656106)
14. Albertini MR, Gan J, Jaeger P, et al: Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma. J Immunother Emphasis Tumor Immunol 19:278-295, 1996 (Pubitemid 26313519)
15. Albertini MR, Hank JA, Schiller JH, et al: Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin Cancer Res 3:1277-1288, 1997 (Pubitemid 27362388)
16. Hank JA, Surfus JE, Gan J, et al: Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin 2 immunocytokine, in Buolamwini JK, Adjei AA (eds): Methods in Molecular Medicine: Novel Anticancer Drug Protocols. Totowa, NJ, Humana Press, 2003, pp 123-131
17. Beal S, Sheiner LB, Boeckmann A, et al: NONMEM User's Guides (1989-2011). Ellicott City, MD, Icon Development Solutions, 2011
18. Smith BP, Vandenhende FR, DeSante KA, et al: Confidence interval criteria for assessment of dose proportionality. Pharm Res 17:1278-1283, 2000
19. Hank JA, Gan J, Ryu H, et al: Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma. Clin Cancer Res 15:5923-5930, 2009
20. Handgretinger R, Anderson K, Lang P, et al: A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 31A:261-267, 1995
21. Yu AL, Uttenreuther-Fischer MM, Huang CS, et al: Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 16:2169-2180, 1998 (Pubitemid 28265055)
22. Kremens B, Hero B, Esser J, et al: Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma. Cancer Immunol Immunother 51:107-110, 2002 (Pubitemid 34230725)
23. Ozkaynak MF, Sondel PM, Krailo MD, et al: Phase I study of chimeric human/murine antiganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: A Children's Cancer Group Study. J Clin Oncol 18: 4077-4085, 2000 (Pubitemid 32038400)
24. Neal ZC, Yang JC, Rakhmilevich AL, et al: Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin Cancer Res 10:4839-4847, 2004 (Pubitemid 38955538)
25. Yang RK, Kalogriopoulos NA, Rakhmilevich AL, et al: Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention. J Immunol 189:2656-2664, 2012
26. Shusterman S, London WB, Gillies SD, et al: Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: A Children's Oncology Group (COG) phase II study. J Clin Oncol 28:4969-4975, 2010
27. Bruno R, Washington CB, Lu JF, et al: Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 56:361-369, 2005 (Pubitemid 41095399)
28. Lu JF, Bruno R, Eppler S, et al: Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779-786, 2008
29. Ng CM, Bruno R, Combs D, et al: Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 45:792-801, 2005 (Pubitemid 40875331)
30. Uttenreuther-Fischer MM, Huang CS, Yu AL: Pharmacokinetics of human-mouse chimeric anti- GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients. Cancer Immunol Immunother 41:331-338, 1995 (Pubitemid 26045103)
31. Cheung NK, Kushner BH, Yeh SD, et al: 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: A phase II study. Int J Oncol 12:1299-1306, 1998 (Pubitemid 28239940)
32. Murray JL, Cunningham JE, Brewer H, et al: Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12:184-193, 1994 (Pubitemid 24020639)
33. Saleh MN, Khazaeli MB, Wheeler RH, et al: Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 52:4342-4347, 1992
34. Gilman AL, Ozkaynak MF, Matthay KK, et al: Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: A report from the Children's Oncology Group. J Clin Oncol 27:85-91, 2009
35. Hank JA, Robinson RR, Surfus J, et al: Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 50:5234-5239, 1990 (Pubitemid 20302968)
36. Kohrt HE, Houot R, Marabelle A, et al: Combination strategies to enhance antitumor ADCC. Immunotherapy 4:511-527, 2012
37. Wu L, Parton A, Lu L, et al: Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: Influence of host immune and tumor markers. Cancer Immunol Immunother 60:61-73, 2011
38. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002 (Pubitemid 34438862)
39. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005 (Pubitemid 41742196)
40. Kowalczyk A, Gil M, Horwacik I, et al: The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells. Cancer Lett 281:171-182, 2009
41. Nowak AK, Robinson BW, Lake RA: Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63:4490-4496, 2003 (Pubitemid 36951021)
42. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
43. Yoshida S, Kawaguchi H, Sato S, et al: An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation. Jpn J Cancer Res 93:816-824, 2002
44. Holden SA, Lan Y, Pardo AM, et al: Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. Clin Cancer Res 7:2862-2869, 2001 (Pubitemid 32911396)
45. Kailayangiri S, Altvater B, Meltzer J, et al: The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer 106:1123-1133, 2012
46. Chang HR, Cordon-Cardo C, Houghton AN, et al: Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer 70:633-638, 1992
47. Heiner JP, Miraldi F, Kallick S, et al: Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res 47:5377-5381, 1987 (Pubitemid 17152948)
48. Zhang S, Cordon-Cardo C, Zhang HS, et al: Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer 73:42-49, 1997 (Pubitemid 27445989)
49. Hamilton WB, Helling F, Lloyd KO, et al: Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer 53:566-573, 1993 (Pubitemid 23069265)
50. Grant SC, Kostakoglu L, Kris MG, et al: Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: A pilot trial. Eur J Nucl Med 23:145-149, 1996 (Pubitemid 26056991)
51. Yoshida S, Fukumoto S, Kawaguchi H, et al: Ganglioside G(D2) in small cell lung cancer cell lines: Enhancement of cell proliferation and mediation of apoptosis. Cancer Res 61:4244-4252, 2001 (Pubitemid 32720995)